Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

990.12 +23.48 (+2.43%)
Streaming Delayed Price Updated: 2:37 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Three Healthcare Buys That Wall Street Loves
These three healthcare stocks are outperforming most of the sector. 
Via The Motley Fool
These 20 Stocks Now Make Up Half Of The S&P 500—Here's Why That's Risky
A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, driven by AI hype, not earnings. 
Via Benzinga
Topics Artificial Intelligence Stocks
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle?
Via Stocktwits
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs. 
Via The Motley Fool
2 Volatile Stocks with Impressive Fundamentals and 1 Facing Headwinds
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Here's How Much $100 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
 
Via Benzinga
Eli Lilly Stock Surges As Analyst Sees More Room To Run
Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to $1,104. 
Via Benzinga
Tech Titans Lead the Charge: A Deep Dive into Sector Performance in the Current Market Rally
The stock market, as of November 10, 2025, continues its robust rally, defying earlier recessionary fears and exhibiting significant growth across several key sectors. At the heart of this resurgence... 
Via MarketMinute
Topics Artificial Intelligence Economy
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.9% in the afternoon session after Leerink Partners upgraded the stock to Outperform from Market Perform and significantly raised... 
Via StockStory
Topics Artificial Intelligence
Stay informed with the top movers within the S&P500 index on Monday.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Markets Cheer As Shutdown End Nears: These 15 Stocks Are Rallying
Markets rallied sharply Monday morning as Congress edged closer to a deal that could end the longest U.S. government shutdown in history. 
Via Benzinga
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration
MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4. 
Via Benzinga
This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
12 Analysts Have This To Say About Eli Lilly
 
Via Benzinga
This Eli Lilly Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
2 Monster Stocks in the Making
There might still be time to get in on the ground floor. 
Via The Motley Fool
2 Growth Stocks with All-Star Potential and 1 We Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades. 
Via The Motley Fool
The Algorithmic Imperative: Navigating AI’s Ethical Labyrinth in American Healthcare
As of November 2025, Artificial Intelligence (AI) has rapidly transitioned from a futuristic concept to an indispensable tool in American healthcare, profoundly reshaping diagnostics, treatment, and... 
Via TokenRing AI
Topics Artificial Intelligence
Is There a Future for Viking Therapeutics?
The weight loss drug company was counted out far too early in the summer, but investors are warming to it again. 
Via The Motley Fool
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump
The companies announced a huge deal that will have implications for investors. 
Via The Motley Fool
Topics World Trade
Organon (OGN) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points
Eli Lilly stock and a pair of AI plays lead this watch list of stocks near buy points as the S&P 500 makes a stand at a key support level. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy
The stock didn't stay down for too long. 
Via The Motley Fool
Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030
It could become the first trillion-dollar pharmaceutical company in the process. 
Via The Motley Fool
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter. 
Via The Motley Fool
Topics Government
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard." 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.